title: Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma.
abstract: Background Arginine deiminase (ADI) is an enzyme that degrades arginine, an amino acid that is important for growth and development of normal and neoplastic cells. Melanoma cells are auxotrophic for arginine, because they lack argininosuccinatesynthetase (ASS), a key enzyme required for the synthesis of arginine. Patients and methods Patients with advanced melanoma were treated with 40, 80 or 160 IU/m(2) ADI-PEG 20 i.m. weekly. Primary endpoints were toxicity and tumor response, secondary endpoints included metabolic response by (18)FDG-PET, pharmacodynamic (PD) effects upon circulating arginine levels, and argininosuccinate synthetase tumor expression by immunohistochemistry. Results 31 previously treated patients were enrolled. The main toxicities were grade 1 and 2 adverse events including injection site pain, rash, and fatigue. No objective responses were seen. Nine patients achieved stable disease (SD), with 2 of these durable for >6 months. Four of the 9 patients with SD had uveal melanoma. PD analysis showed complete plasma arginine depletion in 30/31 patients by day 8. Mean plasma levels of ADI-PEG 20 correlated inversely with ADI-PEG 20 antibody levels. Immunohistochemical ASS expression analysis in tumor tissue was negative in 24 patients, whereas 5 patients had <5 % cells positive. Conclusions ADI-PEG 20 is well tolerated in advanced melanoma patients and leads to consistent, but transient, arginine depletion. Although no RECIST responses were observed, the encouraging rate of SD in uveal melanoma patients indicates that it may be worthwhile to evaluate ADI-PEG 20 in this melanoma subgroup.
authors.affiliation: Department of Medical Oncology, New York University School of Medicine, New York, NY, USA. Patrick_Ott@dfci.harvard.edu
authors.forename: Patrick A
authors.initials: PA
authors.lastname: Ott
authors.forename: Richard D
authors.initials: RD
authors.lastname: Carvajal
authors.forename: Neeta
authors.initials: N
authors.lastname: Pandit-Taskar
authors.forename: Achim A
authors.initials: AA
authors.lastname: Jungbluth
authors.forename: Eric W
authors.initials: EW
authors.lastname: Hoffman
authors.forename: Bor-Wen
authors.initials: BW
authors.lastname: Wu
authors.forename: John S
authors.initials: JS
authors.lastname: Bomalaski
authors.forename: Ralph
authors.initials: R
authors.lastname: Venhaus
authors.forename: Linda
authors.initials: L
authors.lastname: Pan
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
authors.forename: Anna C
authors.initials: AC
authors.lastname: Pavlick
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006867:Hydrolases / Q000493:pharmacokinetics / Q000627:therapeutic use*; D007124:Immunoenzyme Techniques; D008297:Male; D020714:Maximum Tolerated Dose; D008545:Melanoma / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011379:Prognosis; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D015996:Survival Rate; D014018:Tissue Distribution; D014604:Uveal Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary
chemical_list: D011092:Polyethylene Glycols; D006867:Hydrolases; C512527:ADI PEG20